CD4 antibody | YKIX302.9












Rat anti Dog CD4:Alexa Fluor® 488
Rat anti Dog CD4:Alexa Fluor® 647
Rat anti Dog CD4:APC
Rat anti Dog CD4:FITC
Rat anti Dog CD4:Pacific Blue®
Rat anti Dog CD4
Rat anti Dog CD4:RPE
Rat anti Dog CD4:RPE-Cy7
- Product Type
- Monoclonal Antibody
- Clone
- YKIX302.9
- Isotype
- IgG2a
Product Code | Applications | Pack Size | List Price | Quantity |
---|---|---|---|---|
MCA1038A488 | F | 100 Tests/1ml |
![]() |
|
MCA1038A647 | F | 100 Tests/1ml |
![]() |
|
MCA1038APC | F | 100 Tests |
![]() |
|
MCA1038F | F | 100 Tests |
![]() |
|
MCA1038PB | F | 100 Tests/1ml |
![]() |
|
MCA1038GA | C F | 0.1 mg |
![]() |
|
MCA1038PE | F | 100 Tests/1ml |
![]() |
|
MCA1038PECY7 | F | 100 Tests/1ml |
![]() |
Rat anti Dog CD4 antibody, clone YKIX302.9 partially depletes circulating T lymphocytes when administered in vivo, but alone is not sufficient to prolong allograft survival in a canine transplant model (Watson et al. 1993).
Uniquely amongst mammals, canine CD4 is expressed by neutrophils as well as by lymphocyte subsets (Moore et al. 1992).
Product Details
- Target Species
- Dog
- Product Form
- Purified IgG conjugated to Alexa Fluor® 488 - liquid
- Product Form
- Purified IgG conjugated to Alexa Fluor® 647 - liquid
- Product Form
- Purified IgG conjugated to Allophycocyanin (APC) - lyophilised
- Product Form
- Purified IgG conjugated to Fluorescein Isothiocyanate Isomer 1 (FITC) - liquid
- Product Form
- Purified IgG conjugated to Pacific Blue® - liquid
- Product Form
- Purified IgG - liquid
- Product Form
- Purified IgG conjugated to R. Phycoerythrin (RPE) - lyophilized
- Product Form
- Purified IgG conjugated to R. Phycoerythrin (RPE)-Cy7 - lyophilised
- Reconstitution
- Reconstitute with 1.0 ml distilled water
- Reconstitution
- Reconstitute with 1.0 ml distilled water
- Reconstitution
- Reconstitute with 1ml distilled water
Care should be taken during reconstitution as the protein may appear as a film at the bottom of the vial. Bio-Rad recommend that the vial is gently mixed after reconstitution. - Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant.
- Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
0.09% Sodium Azide 1% Bovine Serum Albumin - Preservative Stabilisers
0.09% Sodium Azide 1% Bovine Serum Albumin - Preservative Stabilisers
0.09% Sodium Azide 1% Bovine Serum Albumin 5% Sucrose - Preservative Stabilisers
0.09% Sodium Azide 1% Bovine Serum Albumin - Preservative Stabilisers
0.09% Sodium Azide 1% Bovine Serum Albumin - Preservative Stabilisers
- 0.09% Sodium Azide (NaN3)
- Preservative Stabilisers
0.09% Sodium Azide 1% Bovine Serum Albumin 5% Sucrose - Preservative Stabilisers
- 0.09% Sodium Azide (NaN3)
1% Bovine Serum Albumin
5% Sucrose - Carrier Free
- Yes
- Immunogen
- Canine concanavilin A activated T cell blasts.
- Approx. Protein Concentrations
- IgG concentration 0.05 mg/ml
- Approx. Protein Concentrations
- IgG concentration 0.05 mg/ml
- Approx. Protein Concentrations
- IgG concentration 0.1 mg/ml
- Approx. Protein Concentrations
- IgG concentration 0.05 mg/ml
- Approx. Protein Concentrations
- IgG concentration 1.0 mg/ml
- Fusion Partners
- Spleen cells from immunised DA rats were fused with cells of the Y3/Ag1.2.3 rat myeloma cell line.
Storage Information
- Storage
- Store at +4oC or at -20oC if preferred.
This product should be stored undiluted.
Storage in frost free freezers is not recommended. This product is photosensitive and should be protected from light.
Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. - Storage
- Store at +4oC or at -20oC if preferred.
This product should be stored undiluted.
Storage in frost free freezers is not recommended. This product is photosensitive and should be protected from light.
Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. - Storage
- Prior to reconstitution store at +4oC. Following reconstitution store at +4oC.
DO NOT FREEZE.
This product should be stored undiluted. This product is photosensitive and should be protected from light. Should this product contain a precipitate we recommend microcentrifugation before use. - Storage
- Store at +4oC or at -20oC if preferred.
This product should be stored undiluted.
Storage in frost free freezers is not recommended. This product is photosensitive and should be protected from light.
Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. - Storage
- Store at +4oC or at -20oC if preferred.
This product should be stored undiluted.
Storage in frost free freezers is not recommended. This product is photosensitive and should be protected from light.
Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. - Storage
- Store at +4oC or at -20oC if preferred.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. - Storage
- Prior to reconstitution store at +4oC. Following reconstitution store at +4oC.
DO NOT FREEZE.
This product should be stored undiluted. This product is photosensitive and should be protected from light. Should this product contain a precipitate we recommend microcentrifugation before use. - Storage
- Prior to reconstitution store at +4oC.
After reconstitution store at +4oC.
DO NOT FREEZE. This product should be stored undiluted. This product is photosensitive and should be protected from light. - Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
More Information
- UniProt
- P33705
- Entrez Gene
- CD4
- GO Terms
- GO:0007155 cell adhesion
- GO:0016021 integral to membrane
- GO:0006955 immune response
- GO:0045058 T cell selection
- Acknowledgements
- This product is provided under an intellectual property licence from Life Technologies Corporation. The transfer of this product is contingent on the buyer using the purchase product solely in research, excluding contract research or any fee for service research, and the buyer must not sell or otherwise transfer this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; (c) manufacturing or quality assurance or quality control, or (d) resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad CA 92008 USA or outlicensing@thermofisher.com
- Acknowledgements
- This product is provided under an intellectual property licence from Life Technologies Corporation. The transfer of this product is contingent on the buyer using the purchase product solely in research, excluding contract research or any fee for service research, and the buyer must not sell or otherwise transfer this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; (c) manufacturing or quality assurance or quality control, or (d) resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad CA 92008 USA or outlicensing@thermofisher.com
- Acknowledgements
- This product is provided under an intellectual property licence from Life Technologies Corporation. The transfer of this product is contingent on the buyer using the purchased product solely in research, excluding contract research or any fee for service research, and the buyer must not sell or otherwise transfer this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; (c) manufacturing or quality assurance or quality control, or (d) resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad CA 92008 USA or outlicensing@thermofisher.com
- Acknowledgements
- Cy® and CyDye® are registered trademarks of GE Healthcare
- Regulatory
- For research purposes only
Applications of CD4 antibody
Application Name | Verified | Min Dilution | Max Dilution |
---|---|---|---|
Flow Cytometry | Neat | 1/10 | |
Flow Cytometry | Neat | 1/10 | |
Flow Cytometry | Neat | 1/10 | |
Flow Cytometry | Neat | ||
Flow Cytometry | Neat | 1/5 | |
Flow Cytometry | 1/50 | 1/100 | |
Immunohistology - Frozen | |||
Flow Cytometry | Neat | 1/10 | |
Flow Cytometry | Neat |
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells or 100ul whole blood.
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells or 100ul whole blood.
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells or 100ul whole blood.
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells or 100ul whole blood.
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells or 100ul whole blood.
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells or 100ul whole blood.
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells or 100ul whole blood.
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 1x106 cells in 100ul
Secondary Antibodies Available
Description | Product Code | Applications | Pack Size | List Price | Quantity |
---|---|---|---|---|---|
Goat anti Rat IgG:Alk. Phos. (Mouse Adsorbed) | STAR131A | C E P WB | 1 ml |
![]() |
|
Goat anti Rat IgG:Biotin (Mouse Adsorbed) | STAR131B | C E IF P WB | 0.5 mg |
![]() |
|
Rabbit F(ab')2 anti Rat IgG:Dylight®800 | STAR16D800GA | F IF WB | 0.1 mg |
![]() |
|
Rabbit F(ab')2 anti Rat IgG:FITC | STAR17B | F | 1 mg |
![]() |
|
Rabbit F(ab')2 anti Rat IgG:HRP | STAR21B | C E P RE | 1 mg |
![]() |
|
Goat F(ab')2 anti Rat IgG:FITC (Mouse Adsorbed) | STAR69 | F | 0.5 ml |
![]() |
|
Goat anti Rat IgG:Dylight®800 (Mouse Adsorbed) | STAR71D800GA | F IF WB | 0.1 mg |
![]() |
|
Goat anti Rat IgG:HRP (Mouse Adsorbed) | STAR72 | C E P | 0.5 mg |
![]() |
|
Goat F(ab')2 anti Rat IgG:RPE (Mouse Adsorbed) | STAR73 | F | 0.5 ml |
![]() |
Negative Isotype Controls Available
Description | Product Code | Applications | Pack Size | List Price | Quantity |
---|---|---|---|---|---|
Rat IgG2a Negative Control:Alexa Fluor® 488 | MCA1212A488 | F | 100 Tests/1ml |
![]() |
|
Rat IgG2a Negative Control:Alexa Fluor® 647 | MCA1212A647 | F | 100 Tests/1ml |
![]() |
|
Rat IgG2a Negative Control:Alexa Fluor® 647 | MCA6005A647 | F | 100 Tests/1ml |
![]() |
|
Rat IgG2a Negative Control:APC | MCA6005APC | F | 100 Tests |
![]() |
|
Rat IgG2a Negative Control:FITC | MCA1212F | F | 100 Tests |
![]() |
|
Rat IgG2a Negative Control:FITC | MCA6005F | F | 0.1 mg |
![]() |
|
Rat IgG2a Negative Control:PacificBlue® | MCA6005PB | F | 100 Tests/1ml |
![]() |
|
Rat IgG2a Negative Control:Pacific Blue® | MCA1212PB | F | 100 Tests/1ml |
![]() |
|
Rat IgG2a Negative Control:RPE | MCA1212PE | F | 100 Tests |
![]() |
|
Rat IgG2a Negative Control:RPE | MCA6005PE | F | 100 Tests |
![]() |
|
Rat IgG2a Negative Control:RPE-Cy7 | MCA6005PECY7 | F | 100 Tests/1ml |
![]() |
Product Specific References
Source Reference
-
Cobbold, S. & Metcalfe, S. (1994) Monoclonal antibodies that define canine homologues of human CD antigens: summary of the First International Canine Leukocyte Antigen Workshop (CLAW).
Tissue Antigens. 43 (3): 137-54.
References for CD4 antibody
-
Schaut, R.G. et al. (2016) Recovery of antigen-specific T cell responses from dogs infected with Leishmania (L.) infantum by use of vaccine associated TLR-agonist adjuvant.
Vaccine. 34 (44): 5225-34. -
Gorman, S.D. et al. (1994) Isolation and expression of cDNA encoding the canine CD4 and CD8 alpha antigens.
Tissue Antigens. 43 (3): 184-8. -
Watson, C.J. et al. (1993) CD4 and CD8 monoclonal antibody therapy: strategies to prolong renal allograft survival in the dog.
Br J Surg. 80 (11): 1389-92. -
Papadogiannakis, E.I. et al. (2009) Determination of intracellular cytokines IFN-gamma and IL-4 in canine T lymphocytes by flow cytometry following whole-blood culture.
Can J Vet Res. 73 (2): 137-43. -
Bauer. T.R. Jr. et al. (2006) Correction of the disease phenotype in canine leukocyte adhesion deficiency using ex vivo hematopoietic stem cell gene therapy.
Blood. 108: 3313-20. -
Reis, A.B. et al. (2006) Phenotypic features of circulating leucocytes as immunological markers for clinical status and bone marrow parasite density in dogs naturally infected by Leishmania chagasi.
Clin Exp Immunol. 146: 303-11. -
Araújo, M.S. et al. (2011) Immunological changes in canine peripheral blood leukocytes triggered by immunization with first or second generation vaccines against canine visceral leishmaniasis.
Vet Immunol Immunopathol. 141: 64-75. -
Benyacoub, J. et al. (2003) Supplementation of food with Enterococcus faecium (SF68) stimulates immune functions in young dogs.
J Nutr. 133: 1158-62. -
Bund, D. et al. (2010) Canine-DCs using different serum-free methods as an approach to provide an animal-model for immunotherapeutic strategies.
Cell Immunol. 263: 88-98. -
Estrela-Lima, A. et al. (2010) Immunophenotypic features of tumor infiltrating lymphocytes from mammary carcinomas in female dogs associated with prognostic factors and survival rates.
BMC Cancer. 10: 256. -
Out, T.A. et al. (2002) Local T-cell activation after segmental allergen challenge in the lungs of allergic dogs.
Immunology. 105: 499-508. -
Boggiatto, P.M. et al. (2010) Immunologic indicators of clinical progression during canine Leishmania infantum infection.
Clin Vaccine Immunol. 17: 267-73. -
Mitchell, L. et al. (2012) Clinical and immunomodulatory effects of toceranib combined with low-dose cyclophosphamide in dogs with cancer.
J Vet Intern Med. 26: 355-62. -
Tominaga, M. et al. (2010) Flow cytometric analysis of peripheral blood and tumor-infiltrating regulatory T cells in dogs with oral malignant melanoma.
J Vet Diagn Invest. 22: 438-41. -
Figueiredo, M.M. et al. (2014) Expression of Regulatory T Cells in Jejunum, Colon, and Cervical and Mesenteric Lymph Nodes of Dogs Naturally Infected with Leishmania infantum.
Infect Immun. 82: 3704-12. -
Aresu, L. et al. (2014) VEGF and MMP-9: biomarkers for canine lymphoma.
Vet Comp Oncol. 12: 29-36. -
Costa-Pereira, C. et al. (2015) One-year timeline kinetics of cytokine-mediated cellular immunity in dogs vaccinated against visceral leishmaniasis.
BMC Vet Res. 11 (1): 92. -
Hauck, V. et al. (2016) Increased numbers of FoxP3-expressing CD4(+) CD25(+) regulatory T cells in peripheral blood from dogs with atopic dermatitis and its correlation with disease severity.
Vet Dermatol. 27 (1): 26-e9. -
Riondato, F. et al. (2015) Analytical and diagnostic validation of a flow cytometric strategy to quantify blood and marrow infiltration in dogs with large b-cell lymphoma.
Cytometry B Clin Cytom. Dec 13. [Epub ahead of print] -
Miranda, S. et al. (2007) Characterization of circulating lymphocyte subpopulations in canine leishmaniasis throughout treatment with antimonials and allopurinol.
Vet Parasitol. 144 (3-4): 251-60. -
Yamaya, Y. & Watari, T. (2015) Increased proportions of CCR4(+) cells among peripheral blood CD4(+) cells and serum levels of allergen-specific IgE antibody in canine chronic rhinitis and bronchitis.
J Vet Med Sci. 77 (4): 421-5. -
Schaut, R.G. et al. (2016) Regulatory IgDhi B Cells Suppress T Cell Function via IL-10 and PD-L1 during Progressive Visceral Leishmaniasis.
J Immunol. 196 (10): 4100-9. -
Tagawa, M. et al. (2016) Evaluation of Costimulatory Molecules in Peripheral Blood Lymphocytes of Canine Patients with Histiocytic Sarcoma.
PLoS One. 11 (2): e0150030. -
Munhoz, T.D. et al. (2016) Regulatory T cells in dogs with multicentric lymphoma: peripheral blood quantification at diagnosis and after initial stage chemotherapy
Arq. Bras. Med. Vet. Zootec. 68 (1): 1-9. -
Miller, J. et al. (2015) Humoral and Cellular Immune Response in Canine Hypothyroidism.
J Comp Pathol. 153 (1): 28-37. -
Duz AL et al. (2014) The TcI and TcII Trypanosoma cruzi experimental infections induce distinct immune responses and cardiac fibrosis in dogs.
Mem Inst Oswaldo Cruz. 109 (8): 1005-13. -
Gelain, M.E. et al. (2014) CD44 in canine leukemia: analysis of mRNA and protein expression in peripheral blood.
Vet Immunol Immunopathol. 159 (1-2): 91-6. -
Viana, K.F. et al. (2015) Setting the proportion of CD4+ and CD8+ T-cells co-cultured with canine macrophages infected with Leishmania chagasi.
Vet Parasitol. 211 (3-4): 124-32. -
Viana, K.F. et al. (2016) Application of rapid in vitro co-culture system of macrophages and T-cell subsets to assess the immunogenicity of dogs vaccinated with live attenuated Leishmania donovani centrin deleted parasites (LdCen-/-).
Parasit Vectors. 9: 250. -
Michael HT et al. (2013) Isolation and characterization of canine natural killer cells.
Vet Immunol Immunopathol. 155 (3): 211-7. -
Mitchell, L. et al. (2012) Induction of remission results in spontaneous enhancement of anti-tumor cytotoxic T-lymphocyte activity in dogs with B cell lymphoma.
Vet Immunol Immunopathol. 145 (3-4): 597-603. -
Bonnefont-Rebeix, C. et al. (2016) Characterization of a novel canine T-cell line established from a spontaneously occurring aggressive T-cell lymphoma with large granular cell morphology.
Immunobiology. 221 (1): 12-22. -
Deravi, N. et al. (2017) Specific immunotypes of canine T cell lymphoma are associated with different outcomes.
Vet Immunol Immunopathol. 191: 5-13. -
Bahamondes, F. et al. (2017) Omental adipose tissue is a more suitable source of canine Mesenchymal stem cells.
BMC Vet Res. 13 (1): 166. -
Pinheiro, D. (2011) Phenotypic and functional characterization of a CD4(+) CD25(high) FOXP3(high) regulatory T-cell population in the dog.
Immunology. 132: 111-22. -
Withers, S.S. et al. (2018) Multi-color flow cytometry for evaluating age-related changes in memory lymphocyte subsets in dogs.
Dev Comp Immunol. 87: 64-74. -
Declue, A.E. et al. (2018) Identification of immunologic and clinical characteristics that predict inflammatory response to C. Novyi-NT bacteriolytic immunotherapy.
BMC Vet Res. 14 (1): 119. -
DaSilva, A.V.A. et al. (2018) Morphophysiological changes in the splenic extracellular matrix of Leishmania infantum-naturally infected dogs is associated with alterations in lymphoid niches and the CD4+ T cell frequency in spleens.
PLoS Negl Trop Dis. 12 (4): e0006445. -
Roatt, B.M. et al. (2017) A Vaccine Therapy for Canine Visceral Leishmaniasis Promoted Significant Improvement of Clinical and Immune Status with Reduction in Parasite Burden.
Front Immunol. 8: 217. -
Lisiecka. U. et al. (2019) Evaluation of T regulatory lymphocytes and serum concentration of selected cytokines in dogs with perianal tumors.
Vet Immunol Immunopathol. 207: 10-17. -
Aricò, A. et al. (2013) The role of vascular endothelial growth factor and matrix metalloproteinases in canine lymphoma: in vivo and in vitro study.
BMC Vet Res. 9: 94. -
Aguiar-Soares, R.D.O. et al. (2020) Phase I and II Clinical Trial Comparing the LBSap, Leishmune®, and Leish-Tec® Vaccines against Canine Visceral Leishmaniasis.
Vaccines (Basel). 8 (4)Nov 17 [Epub ahead of print].
Fluorescent Spectraviewer
Watch the Tool Tutorial Video ▸
How to Use the Spectraviewer?
Watch the Tool Tutorial Video ▸
- Start by selecting the application you are interested in, with the option to select an instrument from the drop down menu or create a customized instrument
- Select the fluorophores or fluorescent proteins you want to include in your panel to check compatibility
- Select the lasers and filters you wish to include
- Select combined or multi-laser view to visualize the spectra